key: cord-0749942-obviz80k authors: Mitsuyama, Yumi; Yamakawa, Kazuma; Kayano, Katsuhide; Maruyama, Miho; Wada, Takeshi; Fujimi, Satoshi title: Prolonged enhancement of cytotoxic T lymphocytes in the post-recovery state of severe COVID-19 date: 2021-12-20 journal: J Intensive Care DOI: 10.1186/s40560-021-00591-3 sha: e1bec0e094af1dabcf559f98332120ea1e829e42 doc_id: 749942 cord_uid: obviz80k We evaluated the peripheral blood immune responses of lymphocytes in severe Coronavirus disease 2019 (COVID-19) patients in different stages of recovery using single-cell mass cytometry. The patients with prolonged hospitalization did not show recovery of B lymphocyte counts and CD4-positive T lymphocyte counts but did show abundant CD8-positive T lymphocytes. CD4 and CD8 T cells expressing high levels of T-bet and Granzyme B were more abundant in post-recovery patients. This study showed that cytotoxic Th1 and CD8 T cells are recruited to the peripheral blood long after recovery from COVID-19. The pandemic of coronavirus disease 2019 (COVID-19) is a global public health emergency. Several studies have reported a complex network of peripheral blood immune responses in patients with COVID-19 [1] . However, very little is known about immune cell alterations in critically ill patients who have recovered from COVID-19. We profiled the characteristic peripheral cellular profiles of patients with COVID-19 using single-cell mass cytometry (cytometry by time-of-flight: CyTOF). Peripheral blood mononuclear cells (PBMCs) of six patients who recovered from severe COVID-19, three of whom were discharged (recovered patients: RP) and three who required prolonged hospitalization (hospitalized patients: HP) at the time of blood sampling, were compared with those of healthy donors (HD) ( Table 1) . Patients' blood samples were collected about 3 months after admission. A 43-marker antibody panel was used for CyTOF staining of PBMCs, which were analyzed on a Helios mass cytometer (Fluidigm Sciences Inc.). We identified seven cell subsets and visualized the changes in the cell populations of all samples on a t-distributed Stochastic Neighbor Embedding (t-SNE) map (Fig. 1A) . For comparison of the three groups, data were concatenated within a group and the cell distribution was visualized on a t-SNE map (Fig. 1B) . The contour density of B lymphocytes was lower in the HP group than that in the HD group, whereas that in the RP group had recovered to the same level as that in the HD group. CD4-positive T lymphocytes were fewer in the HP group, followed by the RP group, whereas CD8-positive T lymphocytes were more abundant in the RP and HP groups versus HD group. Natural killer (NK) cells were more abundant in the HP group, followed by the HD group, and were less frequent in the RP group. The frequency of protein expression inside and outside the cells of all samples is shown in the histogram ( Fig. 2A) . The data for each group were concatenated (Fig. 2B) group, followed by the RP group. The number of CD8 T cells highly expressing T-bet and Granzyme B was also higher in the HP and RP groups (Fig. 2C) . We have shown the peripheral blood immune responses of lymphocytes and NK cells in severe COVID-19 patients in different stages of recovery. It has been reported that especially regarding B lymphocyte counts, lymphopenia of patients with acute-phase COVID-19 recovers after polymerase chain reaction tests become negative [2] . Our results suggest that long-term recovery of B lymphocytes might be related to the severity of illness and the current stage of recovery. The NK cell population is reported to be greatly altered in patients with acute COVID-19, with an expansion of the cytokine-producing NK cells and a decrease in the cytolytic NK cells responsible for innate immunity [3] . Although cytolytic NK cells recovered with improvement of the disease, the frequency of cytokine-producing NK cells remained elevated in severe COVID-19. Elevated cytokine-producing NK cells may lead to impaired NK cell cytotoxicity and decreased regulation of cellular and humoral adaptive immune responses [4] . T-bet is the master transcription factor of CD4 T helper type 1 (Th1) cells and plays a major part in protective immunity in cooperation with CD4, CD8 T cells and natural killer T (NKT) cells [5] . Granzyme B is mainly expressed on activated memory CD8 and memory CD4 T cells, NK cells and NKT cells during infection and inflammation, and has important roles in promoting removal of virus-infected cells by cytotoxic T cells and in suppressing the host immune response [6] . Therefore, the high expression of T-bet and Granzyme B in CD4 and CD8 T cells indicates increased cytotoxicity of lymphocytes. Previous reports showed that cytotoxicity is enhanced in CD4 and CD8 T cells in the acute phase of severe COVID-19, and the elevation in cytotoxic CD8 T cell counts persists after recovery [7, 8] . The present study also revealed that the persistence of T cells highly expressing T-bet and Granzyme B in the recovered COVID-19 patients might indicate prolonged suppression of the immune response and an unrecovered inflammatory process. Comparing the RP and HP groups, although recovery of B lymphocytes was restored in the RP group, the recruitment of cytotoxic T cells to the peripheral blood persisted in both post-COVID-19 groups. This may suggest that the activation of cellular immunity is more prolonged than that of humoral immunity in COVID-19, depending on the severity of Ready to submit your research Ready to submit your research ? Choose BMC and benefit from: ? Choose BMC and benefit from: Single-cell multi-omics analysis of the immune response in COVID-19 Comprehensive mapping of immune perturbations associated with severe COVID-19 Abnormality in the NK-cell population is prolonged in severe COVID-19 patients Flattening the COVID-19 curve with natural killer cell based immunotherapies The evolving role of T-bet in resistance to infection Cytotoxic and non-cytotoxic roles of the CTL/NK protease granzyme B Imbalance of regulatory and cytotoxic SARS-CoV-2-reactive CD4+ T cells in COVID-19 Alterations in T and B cell function persist in convalescent COVID-19 patients Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations None. Authors' contributions YM and KY undertook study design; YM enrolled patients and acquired data; KK and MM processed patient samples. KK performed CyTOF. YM, KY, TW and SF drafted the manuscript and revised it critically. KY organized and supervised the conduction of the study. All authors read and approved the final manuscript. This work was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology, Japan (19H03759). The datasets analyzed during the current study are available from the corresponding author on reasonable request. The study was approved by the Institutional Review Board of Osaka General Medical Center [approval number: C201912002]. Written informed consent was obtained from all patients. Not applicable. The authors declare that they have no competing interests.